StockData
Q32 Bio Inc. logo

Q32 Bio Inc. (QTTB) company profile

QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$8.53−0.10 (-1.16%)

Close on Nov 18, 2026Market cap $253.93MP/E –Yield –

About Q32 Bio

Pharmaceutical Preparations, SIC 2834

Q32 Bio Inc. is a clinical-stage biotechnology company that develops biological therapies to restore immune balance in patients affected by autoimmune and inflammatory diseases. Its primary product candidate is bempikibart, a fully human monoclonal antibody antagonist that blocks signaling driven by interleukin-7 and thymic stromal lymphopoietin. The company develops bempikibart for autoimmune disorders, focusing specifically on individuals with alopecia areata. It has also created a proprietary tissue-targeted complement inhibitor platform that includes pre-clinical therapies such as ADX-096. Because its product candidates remain in development, the company has not commercialized products or established a commercial customer base.

The company operates in the United States and maintains its corporate headquarters and principal executive offices in Waltham, Massachusetts. As a clinical-stage enterprise, it has no commercial storefronts or physical distribution footprint. Its clinical trial evaluations include studies involving clinical trial participants, with more than 150 individuals dosed with bempikibart across completed and ongoing clinical trials.

Summary of the business section of Q32 Bio's latest annual report, written by StockData.

Company profile

Company

Legal name
Q32 Bio Inc.
Headquarters
Waltham, MA
Address
830 Winter Street 02451
Phone
(781) 999-0232
Website
q32bio.com
Employees
24, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts, USA

Stock & identifiers

Ticker
QTTB
Former tickers
FIXX until Mar 27, 2024
Exchange
Nasdaq
IPO date
Mar 29, 2018
Shares outstanding
30M, Aug 3, 2026
Public float
$10.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-166 reverse, May 9, 2024; 1-for-18 reverse, Mar 26, 2024
SEC CIK
1661998
CUSIP
746964105
ISIN
US7469641051
FIGI
BBG00CTTJWQ9
Share class FIGI
BBG00CTTJWS7
LEI
549300RWKPJEFTM3K452
EIN
47-3468154

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jodie Pope MorrisonCEO, Director340,038
Lee KalowskiCFO and President137,170
Shelia M. VioletteChief Scientific Officer163,131
Jason CampagnaChief Medical Officer37,500
Mary ThistleDirector–
David S. GrayzelDirector2,092,106
Kathleen LaporteDirector5,431
Diyong XuDirector625,000
Mark T. IwickiDirector–
Arthur TzianabosDirector7,983
Sven Ante LundbergDirector1,200
Isaac MankeDirector53,521
Genesis GP LLC OrbiMedDirector–
Capital GP VII LLC OrbiMedDirector3,502,987
Advisors Llc OrbimedDirector2,252,987

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Albert Seymour Ph D
$0$0$880.80K$15–
FY2025
Jodie Morrison
$1.56M$1.21M$880.80K$15–
FY2025
Paul Alloway Ph DJD
$0$0$880.80K$15–
FY2024
Albert Seymour Ph D
$0$0$2.20M$1517–
FY2024
Jodie Morrison
$6.00M$2.09M$2.20M$1517–
FY2024
Paul Alloway Ph DJD
$758.14K$708.39K$2.20M$1517–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Jodie Morrison
Chief Executive Officer and Director
$645.60K$335.28K$220.79K$355.08K$2.12K$1.56M-74%
Lee Kalowski
Chief Financial Officer and President
$565.00K$135.26K$59.12K$226.00K$1.77K$987.15K-65%
Shelia Violette
Chief Scientific Officer
$455.00K$95.25K$37.31K$182.00K$4.88K$774.45K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 29, 2018
Offer price
$16.00
Securities offered
9,000,000
Gross proceeds
$144.00M
Exchange
Nasdaq
First trading day
Mar 28, 2018
First-day close
$18.66+16.6%
Lock-up ends (est.)
Sep 24, 2018

“Per Share Total Public offering price $ 16.00 $ 144,000,000 Underwriting discount(1) $ 1.12 $ 10,080,000 Proceeds, before expenses, to us $ 14.88 $ 133,920,000 (1) We refer you to “Underwriting” beginning on page 166 for additional information regarding underwriting compensation.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 24 full-time employees, of which 3 have M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?